Sionna Therapeutics Reports First Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Guggenheim on Sionna Therapeutics (SION): 'We think these readouts are highly meaningful catalysts for the company'
May 12, 2026 12:20 PM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $50.00 price target on Sionna Therapeutics (NASDAQ: SION).
The analyst comments "This morning, SION announced 1Q26 earnings. The company ended 1Q26 with $289.9MM in cash and guided cash runway until 2028. Key updates are: (1) Phase IIa PreciSION study (n~16) has recently completed patient enrollment, and the company has reiterated topline readout guidance for summer 2026 (we think around... More
